DLBCL

Related by string. * * cell lymphoma DLBCL . Cell Lymphoma DLBCL . refractory DLBCL *

Related by context. All words. (Click for frequent words.) 70 relapsed refractory 69 non Hodgkin lymphomas 68 NSCLC 68 chronic lymphocytic leukemia CLL 67 CLL 67 leukemia CLL 67 CHOP chemotherapy 66 indolent NHL 66 follicular lymphoma 66 CLL SLL 66 cell lymphomas 66 hepatocellular carcinoma HCC 65 lymphomas 65 metastatic renal cell carcinoma 64 leukemia AML 64 acute myeloid leukemia AML 64 acute myelogenous leukemia AML 64 pancreatic adenocarcinoma 64 small lymphocytic lymphoma 64 Non Hodgkin lymphoma 64 Diffuse Large B 64 squamous cell carcinoma SCC 64 cell lymphoma DLBCL 63 previously untreated follicular 63 lupus nephritis 63 heavily pretreated 63 Follicular lymphoma 63 bendamustine 63 Chronic Lymphocytic Leukemia CLL 63 prostate cancer CaP 63 imatinib resistant 62 renal cell carcinoma 62 follicular lymphomas 62 rituximab 62 Gleevec resistant 62 subtype 62 leukemia ALL 62 metastatic RCC 61 MALT lymphoma 61 Fludarabine 61 Hodgkin lymphoma HL 61 HNSCC 61 multiple myeloma MM 61 recurrent glioblastoma multiforme 61 Fludara 61 xenograft models 61 HRPC 61 mRCC 61 papillary renal cell carcinoma 61 epithelial tumors 61 cytogenetic responses 61 Non Hodgkin Lymphomas 61 advanced NSCLC 61 lymphocytic leukemia 61 T2DM 61 soft tissue sarcomas 61 superficial bladder cancer 61 anti leukemic 61 rituximab refractory 61 GISTs 61 pheochromocytoma 61 Chronic lymphocytic leukemia 60 imatinib Gleevec 60 heavily pretreated patients 60 imatinib Gleevec ® 60 carcinoma 60 stage IIIB 60 hepatocellular carcinoma 60 Non Hodgkin 60 Nilotinib 60 medullary thyroid cancer 60 recurrent NSCLC 60 SCCHN 60 HER2 positive metastatic breast 60 pomalidomide 60 histologies 60 evaluable 60 myeloproliferative diseases 60 relapsed MM 60 glioblastoma 60 acute leukemias 60 brain metastases 60 chlorambucil 60 Toxicities 60 dasatinib 60 cell lymphoma CTCL 60 glioblastoma multiforme GBM 60 HBeAg positive 60 recurrent GBM 60 nonsmall cell lung cancer 60 Metastatic 60 node metastases 59 imatinib therapy 59 fludarabine 59 decitabine 59 Cell Lymphoma 59 lymphocytosis 59 HER2 negative 59 chronic myeloid leukemia CML 59 pancreatic neuroendocrine tumors 59 PCa 59 Follicular Lymphoma 59 operable breast cancer 59 HCV infection 59 osteosarcomas 59 grade gliomas 59 papillary thyroid carcinoma 59 metastatic malignant melanoma 59 follicular NHL 59 chronic HCV 59 CLL cells 59 ErbB2 positive 59 indolent lymphoma 59 malignant pleural mesothelioma 59 renal tumors 59 ADPKD 59 carboplatin paclitaxel 59 neoadjuvant chemotherapy 59 Hodgkin lymphoma NHL 59 breast carcinoma 59 seminoma 59 KRAS mutations occur 59 Leukemias 59 adenocarcinomas 59 mutated KRAS 59 leukaemias 59 biologic therapy 59 ulcerative colitis UC 59 Doxil ® 59 hematologic malignancies 59 gemcitabine carboplatin 59 thymoma 59 tumor necrosis 59 Telintra 59 neuroendocrine tumors 59 HCV infected 59 bleomycin 59 azacitidine 59 FOLFIRI 59 chemotherapy regimens 59 refractory AML 59 chemoradiotherapy 59 squamous histology 59 colon carcinoma 59 vandetanib 59 myelodysplastic syndrome MDS 59 Epratuzumab 59 non metastatic osteosarcoma 58 autoantibody positive 58 posaconazole 58 5FU 58 mCRC patients 58 cytopenias 58 HER2 positive breast cancer 58 breast carcinomas 58 Enzastaurin 58 Waldenstrom macroglobulinemia 58 MGd 58 cell lymphoma 58 differentiated thyroid 58 lymphoproliferative disorders 58 solid tumors 58 evaluable patients 58 multiple myeloma 58 locoregional 58 complete remissions 58 CVP chemotherapy 58 CPOP R 58 carcinomas 58 CsA 58 follicular non 58 gemcitabine Gemzar ® 58 colorectal carcinoma 58 metastatic lung cancer 58 Myelofibrosis 58 pancreatic NET 58 IFN α 58 MGUS 58 hepatocellular carcinomas 58 axitinib 58 panobinostat 58 GBM tumors 58 severe neutropenia 58 HER2 positive 58 bone metastasis 58 histologically confirmed 58 refractory CML 58 fludarabine cyclophosphamide 58 PsA 58 gefitinib Iressa 58 TKI therapy 58 metastatic melanoma 58 relapsing remitting multiple sclerosis 58 liver metastases 58 hematologic toxicity 58 vinorelbine 58 pegylated liposomal doxorubicin 58 systemic lupus erythematosus SLE 58 castration resistant prostate cancer 58 demyelinating 58 immunocompetent 58 lymphoid malignancies 58 prostate carcinoma 58 alkylating agent 58 adverse cytogenetics 58 cell carcinoma 58 biliary tract cancer 58 adenocarcinoma 58 Vidofludimus 58 Ph + 58 cabazitaxel 58 Rituximab 58 platinum refractory 58 refractory NSCLC 58 carcinoid tumors 58 Amrubicin 58 renal cell carcinomas 58 abiraterone acetate 58 cutaneous T 57 HBeAg negative 57 acute myeloid 57 metastatic malignant 57 chemotherapy docetaxel 57 lymphoma subtypes 57 Ibritumomab Tiuxetan 57 docetaxel chemotherapy 57 etoposide 57 recurrent malignant glioma 57 advanced hepatocellular carcinoma 57 hepatitis C genotype 57 azacytidine 57 sunitinib malate 57 IV NSCLC 57 mTOR inhibitors 57 Cutaneous T 57 systemic lupus erythematosus 57 EGFR mutations 57 cell malignancies 57 basal cell carcinoma BCC 57 androgen independent 57 unresectable 57 subtypes 57 PCNSL 57 epirubicin 57 acute myeloid leukemia 57 chronic myelogenous leukemia CML 57 relapsed AML 57 B CLL 57 Acute myeloid leukemia 57 chemoradiation 57 diagnosed glioblastoma multiforme 57 follicular lymphoma FL 57 IMGN# 57 KRAS wild 57 adriamycin 57 daunorubicin 57 receptor tyrosine kinase inhibitor 57 myelofibrosis polycythemia vera 57 G CSF 57 malignant lymphoma 57 neuroblastomas 57 radiochemotherapy 57 EGFR mutation positive 57 bortezomib 57 relapsed refractory AML 57 FOLPI 57 K ras mutations 57 octreotide LAR 57 sunitinib 57 metastatic prostate cancer 57 NMIBC 57 HER2 positive cancers 57 lung metastases 57 metastatic colorectal cancer 57 gastrointestinal stromal tumors 57 interferon IFN 57 seminomas 57 metastases 57 pDC 57 HCV genotype 1 57 invasive lobular carcinoma 57 P. aeruginosa 57 nonmetastatic 57 medically inoperable 57 prostate cancer AIPC 57 hypomethylating agents 57 refractory indolent non 57 B Cell Lymphoma 57 paragangliomas 57 mycophenolate mofetil 57 sarcomatoid 57 recurrent glioblastoma 57 PSADT 57 pan HDAC inhibitor 57 dasatinib Sprycel 57 ovarian carcinoma 57 cyclophosphamide doxorubicin vincristine 57 chronic GVHD 57 lung carcinomas 57 cisplatin resistant 57 mitoxantrone 57 anaplastic 57 lenalidomide Revlimid R 57 CVP cyclophosphamide vincristine 57 mg/m2 dose 57 seropositive patients 57 Hepatocellular Carcinoma HCC 57 cutaneous melanoma 57 ribavirin therapy 57 Chronic lymphocytic leukemia CLL 57 erlotinib Tarceva ® 57 thrombocytopenic patients 57 ara C 57 serous ovarian cancer 57 activating mutations 57 tumor xenograft models 57 squamous cell lung cancer 57 Non Hodgkin Lymphoma 57 malignant pleural mesothelioma MPM 57 Adjuvant chemotherapy 57 resectable 57 nutlin 3a 57 Rituxan rituximab 57 KRAS mutant tumors 57 lymphoma CTCL 57 peripheral blood mononuclear 57 neoplasia 56 temsirolimus 56 GvHD 56 colorectal cancer CRC 56 dasatinib Sprycel ® 56 relapsed SCLC 56 carcinoid 56 histological subtype 56 thalidomide Thalomid 56 metachronous 56 prostate cancer CRPC 56 malignant lymphomas 56 myeloid 56 Relapsed Refractory 56 anterior uveitis 56 neoadjuvant therapy 56 Alemtuzumab 56 enzastaurin 56 cytotoxic chemotherapy 56 essential thrombocythemia 56 urothelial carcinoma 56 splenectomized patients 56 Glioblastoma Multiforme 56 pulmonary metastases 56 relapsed ovarian cancer 56 non Hodgkin lymphoma 56 candidemia 56 AA Amyloidosis 56 systemic ALCL 56 standard chemotherapy regimens 56 Voreloxin 56 Carcinoma 56 virological response 56 Castration Resistant Prostate Cancer 56 adjuvant therapy 56 T#I mutation 56 hepatorenal syndrome 56 estrogen receptor negative 56 Myelodysplastic Syndrome MDS 56 mycosis fungoides 56 hepatic metastases 56 T#I [002] 56 lumiliximab 56 myeloproliferative 56 nab paclitaxel 56 HER2 overexpression 56 EGFR inhibitors 56 colorectal liver metastases 56 hA# 56 JAK2 V#F 56 #mg/m# [001] 56 cetuximab 56 Akt activation 56 CTCL 56 relapsed refractory multiple myeloma 56 Sjögren syndrome 56 MabCampath 56 Cyclophosphamide 56 locoregional disease 56 relapsing remitting 56 myeloablative 56 metastatic lesions 56 Lenalidomide 56 bladder cancers 56 patients evaluable 56 gastrointestinal stromal tumor GIST 56 pulmonary exacerbations 56 neoadjuvant treatment 56 preoperative chemotherapy 56 BCG refractory 56 atypical hemolytic uremic syndrome 56 thromboembolic events 56 TNF antagonist 56 completely resected 56 low dose cytarabine 56 pleomorphic 56 lymphocyte 56 JMML 56 SUTENT 56 antiangiogenic therapy 56 neoadjuvant 56 milatuzumab 56 refractory CLL 56 IL 1ß 56 Glioma 56 SSc 56 HDACi 56 estramustine 56 untreated de novo 56 Pemetrexed 56 bladder carcinoma 56 tumor progression 56 remission induction 56 taxane therapy 56 glufosfamide 56 essential thrombocythemia ET 56 estrogen receptor progesterone receptor 56 refractory acute myeloid 56 chronic periodontitis 56 Irinotecan 56 KRAS status 56 cell lymphoma ALCL 56 stage IIIb IV 56 androgen deprivation 56 trabectedin 56 HBeAg negative chronic hepatitis 56 Trastuzumab 56 neoplasms 56 diagnosed multiple myeloma 56 PROSTVAC VF 56 febrile neutropenia 56 Myelodysplastic syndromes MDS 56 melphalan prednisone 56 imatinib 56 Atypical Hemolytic Uremic Syndrome 56 acute GvHD 56 temozolomide 56 rheumatoid arthritis RA 56 neoplastic 56 5-FU/LV 56 cinacalcet 56 gemcitabine 56 Ofatumumab 56 HSCT 56 pancreatic carcinoma 56 MCyR 56 elacytarabine 56 hypereosinophilic syndrome 56 docetaxel Taxotere ® 56 nucleoside analog 56 NRTIs 56 activin 56 lymphoid cells 56 pharmacokinetic interactions 55 Follicular 55 refractory CTCL 55 Arranon 55 ALT flares 55 trans retinoic acid 55 Dasatinib 55 gastric cancers 55 lenalidomide dexamethasone 55 myeloproliferative neoplasms 55 CYT# potent vascular disrupting 55 sorafenib Nexavar 55 gastric carcinoma 55 alkylating agents 55 antitumor activity 55 antitumor effect 55 Pharmacokinetics PK 55 topotecan 55 refractory chronic myeloid 55 IFN gamma 55 cytoreduction 55 cisplatin 55 temozolomide TMZ 55 Seliciclib 55 prednisone prednisolone 55 pT3 55 Relapsed 55 trastuzumab Herceptin R 55 leukemia CML 55 galiximab 55 fibrotic disease 55 PKC# 55 Platinol 55 rituximab refractory follicular 55 FOLFOX 55 acute promyelocytic leukemia 55 COX2 55 Xanafide 55 nodular 55 Acute lymphoblastic leukemia 55 Renal cell carcinoma 55 CR nPR 55 recurrent VTE 55 histologically 55 mutated KRAS gene 55 cytokine refractory 55 cell acute lymphoblastic 55 intravesical therapy 55 ER CHOP 55 metastatic gastric 55 cutaneous squamous cell carcinoma 55 cytarabine daunorubicin 55 BARACLUDE ® 55 sporadic ALS 55 cyclophosphamide methotrexate 55 refractory multiple myeloma 55 mouse xenograft models 55 Akt inhibitor 55 FLT3 55 HCV SPRINT 55 IFN beta 55 anthracyclines 55 fulvestrant 55 sorafenib Nexavar ® 55 EGFR mutation 55 sunitinib Sutent ® 55 Fluorouracil 55 indolent lymphomas 55 EGFr 55 antigen CD# 55 mapatumumab 55 metastatic neuroendocrine tumors 55 KRAS mutations 55 Erlotinib 55 squamous 55 IFN alpha 55 ABCB1 55 Anthracycline 55 rituximab Rituxan 55 uveal melanoma 55 seliciclib 55 TNF α 55 tyrosine kinase inhibitors 55 Blinatumomab 55 gastrointestinal stromal tumor 55 DAPT 55 nilotinib 55 DMARDs 55 locoregional recurrence 55 immunoreactivity 55 refractory 55 severe oral mucositis 55 brain tumor glioblastoma multiforme 55 cervical lymph nodes 55 ccRCC 55 PEGylated interferon beta 1a 55 anticancer therapy 55 myeloproliferative disorders 55 cutaneous T cell 55 lymphoid 55 Non Hodgkins lymphoma 55 EGFR expressing 55 relapsed refractory aggressive 55 missense mutations 55 metastatic 55 HGPIN 55 cisplatin chemotherapy 55 oblimersen 55 dacarbazine 55 castrate resistant prostate cancer 55 Epstein Barr virus EBV 55 nonalcoholic steatohepatitis NASH 55 graft dysfunction 55 HER2 + 55 TREANDA 55 cytogenetic response 55 IGF 1R 55 haematologic 55 B lymphocyte 55 ritonavir boosted 55 papillary 55 Chronic Myelogenous Leukemia CML 55 histologic subtypes 55 de novo AML 55 metastatic disease 55 SSc patients 55 Bosutinib 55 Hematologic 55 squamous cell carcinoma 55 histologic subtype 55 hematological malignancy 55 pT2 55 PAOD 55 Multiple Myeloma MM 55 refractory follicular 55 demonstrated antitumor activity 55 relapsed indolent 55 germinal center 55 ERBB2 55 lymph node metastases 55 EpCAM 55 amrubicin 55 leukemias 55 fosbretabulin 55 polycythemia vera PV 55 FGFR1 55 tigecycline 55 Glioblastoma 55 cholangiocarcinoma 55 metastatic renal cell 55 Cholangiocarcinoma 55 HCV genotypes 55 follicular thyroid cancer 55 MabThera Rituxan 55 hepatoma 55 paclitaxel Taxol 55 dacarbazine DTIC 55 Papillary 55 HCV infections 55 medulloblastomas 55 viral kinetics 55 trastuzumab Herceptin ® 55 metastatic bladder 55 plus gemcitabine 55 PegIFN RBV 55 DMARD 55 diagnosed Ph + 55 cilengitide 55 calcitriol 55 micrometastases 55 radiotherapy RT 55 lymphoma 55 leukemic cell 55 hepatocellular cancer 55 CD4 + CD# 55 tumor recurrence 55 MAPK pathway 55 astrocytomas 55 untreated AML 55 angiogenesis inhibitor 55 interferon 55 metastatic cancer 55 progressive PsA 55 cell lung cancer 55 myelofibrosis 55 AML MDS 55 Retreatment 55 hormone receptor negative 55 p# biomarker 55 localized renal 55 Myelodysplastic syndromes 54 breast cancer subtypes 54 BRAF inhibitor 54 pediatric acute lymphoblastic 54 recurrent ovarian cancer 54 hormone refractory prostate cancer 54 micafungin 54 esophageal carcinoma 54 sorafenib 54 carcinoids 54 distant metastases 54 aHUS 54 lymphoproliferative disorder 54 plasmacytoid 54 EGFR HER2 54 Rheumatoid Arthritis RA 54 TRAIL induced apoptosis 54 standard chemotherapy regimen 54 ibritumomab tiuxetan 54 familial amyloidotic polyneuropathy FAP 54 cell lymphoma MCL 54 ALK inhibitor 54 paraganglioma 54 Neulasta ® 54 tumor regression 54 Talabostat 54 myelodysplastic syndromes MDS 54 T1c 54 cardiac toxicity 54 stage IIIA 54 estrogen receptor ER 54 malignancies 54 Raf MEK ERK 54 NOMID 54 refractory ovarian cancer 54 juvenile idiopathic arthritis 54 lymphocytic 54 basal cell nevus syndrome 54 hyperplastic 54 Burkitt lymphoma 54 mediated immunity 54 AZT zidovudine Retrovir 54 relapsed follicular 54 BRAF mutation 54 colorectal tumors 54 HoFH 54 cyclophosphamide 54 Mantle Cell Lymphoma 54 nucleoside analogues 54 ZACTIMA 54 SUVmax 54 chronic myeloid 54 COPAXONE R 54 Acute Myeloid Leukemia AML 54 trastuzumab 54 sunitinib Sutent 54 doxorubicin cyclophosphamide 54 neurologic progression 54 glioblastomas 54 Antitumor Activity 54 situ LCIS 54 myelosuppression 54 pertuzumab 54 veltuzumab 54 monotherapy 54 EURIDIS 54 invasive ductal carcinoma 54 IIIb 54 malignant neoplasm 54 relapsed acute lymphoblastic 54 hyperoxaluria 54 prostate cancer PCa 54 CAMMS# 54 untreated chronic lymphocytic 54 polyposis 54 castrate resistant 54 relapsing multiple sclerosis 54 blastic phase 54 epithelioid 54 chronic HBV infection 54 metastatic hormone refractory 54 nasopharyngeal carcinoma 54 secondary hyperparathyroidism 54 gastric adenocarcinoma 54 FOLFOX chemotherapy 54 thrombocytopenic 54 diabetes mellitus DM 54 gemcitabine Gemzar 54 mycophenolate mofetil MMF 54 ixabepilone 54 peginterferon 54 YONDELIS 54 associated lymphoid tissue 54 xenografts 54 Philadelphia Chromosome Positive 54 common hematologic malignancy 54 plus dexamethasone 54 severe sepsis 54 VT VF 54 allogeneic SCT 54 intratumoral injection 54 medulloblastoma 54 Fludara ® 54 CCyR 54 lung fibrosis 54 underwent resection 54 HBeAg positive patients 54 generalized seizures 54 distant metastasis 54 PNH patients 54 metastatic breast cancer 54 intermittent dosing 54 invasive bladder 54 TNFalpha 54 C. albicans 54 vWD 54 childhood leukemias 54 paclitaxel Taxol ® 54 NRTI resistance 54 Taxotere ® 54 non squamous histology 54 Metastatic Colorectal Cancer 54 MYCN amplification 54 biochemical relapse 54 isolated systolic hypertension 54 HCV genotype 54 chemoresistant 54 thyroid carcinoma 54 tumor regressions 54 Sezary syndrome 54 imatinib resistance 54 tyrosine kinase inhibitor 54 complete cytogenetic 54 virological failure 54 EGFR tyrosine kinase inhibitors 54 cyclin E 54 EGFRvIII 54 Response Evaluation Criteria 54 SJIA 54 mitomycin 54 Flu Cy 54 bosentan 54 castration resistant 54 lymphoblastic leukemia 54 BCR ABL 54 tumor shrinkage 54 elotuzumab 54 CD# [002] 54 polycythemia vera essential thrombocythemia 54 Chronic myeloid leukemia 54 effector function 54 evaluating REVLIMID 54 transgene expression 54 histone deacetylase HDAC inhibitor 54 rindopepimut 54 huN# DM1 54 proliferative diabetic retinopathy 54 Chronic Myeloid Leukemia 54 endometrial carcinoma 54 immunomodulatory therapy 54 tyrosine kinase inhibitors TKIs 54 concurrent chemoradiation 54 Decitabine 54 myeloproliferative disorder 54 LHRH receptor positive 54 papillary carcinoma 54 mucinous 54 curative resection 54 HGS ETR1 54 urothelial 54 DLC1 54 familial ALS 54 BRAF V#E 54 JAK2 enzyme 54 TTR amyloidosis 54 lamivudine refractory patients 54 rs# [004] 54 transitional cell carcinoma 54 cyclophosphamide Cytoxan 54 precursor acute lymphoblastic 54 VEGF inhibitors 54 ependymoma 54 prostate adenocarcinoma 54 HeFH 54 lymphopenia 54 cell carcinomas 54 IV metastatic melanoma 54 poorer prognosis 54 orthotopic 54 Cloretazine 54 TACE 54 pegylated interferon alpha 54 juvenile idiopathic arthritis JIA 54 allogeneic stem cell 54 mesotheliomas 54 T1DM 54 alfa 2a 54 coinfected patients 54 lung tumors 54 Etanercept 54 beta 1a 54 VELCADE 54 Soft Tissue Sarcoma 54 samalizumab 54 hormone refractory 54 invasive fungal infections 54 CP CPPS 54 ON #.Na 54 stage IIIb 54 TLR3 54 hypercalcemia 54 progressive neurodegenerative disorder 54 TORISEL 54 myeloma cells 54 gamma secretase inhibitor 54 antithymocyte globulin 54 neoplastic cells 54 JAK3 54 mildly symptomatic 54 nonresponders 54 T#I mutant 54 adjuvant tamoxifen 54 follicular Non Hodgkin 54 geographic atrophy 54 elevated triglyceride levels 54 neoplasm 54 urothelial bladder cancer 54 Cloretazine R 54 TEAEs 54 Valortim R 54 HDAC Inhibitor 54 hematological cancers 54 Severe Sepsis 54 noninfectious uveitis 54 Newly Diagnosed Multiple Myeloma 54 benign prostatic hypertrophy BPH 54 premalignant 54 interstitial pneumonia 54 Aurora kinase 54 virologic response 54 cetuximab Erbitux R 54 tumoral 54 lung adenocarcinomas 54 anemia neutropenia 54 OHR/AVR# 54 Temsirolimus 54 pegfilgrastim 54 Acute Myeloid Leukaemia AML 54 leukemic 54 fluorouracil leucovorin 54 interferon alfa 2a 54 dose cytarabine 54 Omacetaxine 54 NNRTI resistance 54 relapsing remitting MS 53 progesterone receptor negative 53 ribavirin RBV 53 induces apoptosis 53 Cytoxan 53 VZV 53 antiretroviral naive 53 somatostatin analog 53 adjuvant chemotherapy 53 Gemzar ® 53 EGFR TKI 53 5 fluorouracil 53 paricalcitol 53 fallopian tube carcinoma 53 boosted protease inhibitor 53 superinfection 53 Ph + acute lymphoblastic 53 rFVIIa 53 LHRH agonists 53 adecatumumab 53 prednisolone chemotherapy 53 partial remissions 53 leukaemic stem cells 53 chronic HCV infection 53 selective modulator 53 biochemical recurrence 53 progression TTP 53 disease progression 53 CIN3 53 evaluable subjects 53 malignancy 53 Acute Myeloid Leukemia 53 pegylated interferon alfa 2b 53 antihypertensive therapy 53 busulfan 53 teriflunomide 53 achieved sustained virological 53 Campath alemtuzumab 53 pro angiogenic 53 activating mutation 53 microtubule targeting 53 pCR 53 ofatumumab 53 mRNA expression 53 metastatic GIST 53 Pegylated Interferon 53 FasL 53 cancer mCRC 53 EGFR TKIs 53 HCV 53 TACI Ig 53 Renal Cell Carcinoma RCC 53 TEMODAL 53 skeletal metastases 53 anthracycline containing 53 liver histology 53 Velcade bortezomib 53 MTHFR 53 EGFR mutant 53 CMV infection 53 chronic eosinophilic leukemia 53 depsipeptide 53 tumors 53 efalizumab 53 IGF IR 53 IDH1 mutation 53 Kaplan Meier analysis 53 Prognostic factors 53 FLT3 mutations 53 somatostatin analogs 53 interleukin IL -# 53 cervical carcinoma 53 GIST 53 endometrioid 53 Gleevec imatinib mesylate 53 Carcinoid tumors 53 missense mutation 53 fluorouracil 53 diabetic nephropathy 53 IFN ß 53 Sipuleucel T 53 intestinal metaplasia 53 antibody mediated 53 nucleoside analogue 53 Amigal 53 refractory colorectal cancer 53 Carboplatin 53 imetelstat 53 gefitinib 53 Pixantrone 53 HLA DR 53 anti angiogenic agents 53 virologic failure 53 prostate cancer mCRPC 53 Acute myelogenous leukemia 53 GIST tumors

Back to home page